Strand Life Sciences has announced that it has entered into a research collaboration with Elan Pharmaceuticals aimed towards supporting Elan's drug discovery efforts.
This collaboration allows Elan to access Strand's technologies and achieve customized solutions for internal research programs.
The agreement incorporates access to Strand's extensive in silico technology portfolio including predictive modeling for efficacy and ADMET, custom library design, QSAR and pharmacophore modeling, structure based drug design, data and visual mining and consulting experience.
“We believe that Strand's portfolio of technologies are leading edge and look forward to working with them to advance our discovery efforts,” said Dale Schenk, Chief Scientific Officer, Elan Pharmaceuticals.
“We are very excited about this opportunity and are confident that this will be a mutually beneficial relationship,” said Kas Subramanian, Ph.D., CSO of Strand Life Sciences.
“Our existing technology platform coupled with our consulting experience allows us to rapidly develop and deploy tailored solutions that enable decision making.”